PD-L1

[Clinical and Translational Oncology] Pretreated specimens were evaluated by immunohistochemistry for programmed cell death protein 1 and its ligand, densities of tumor infiltrative lymphocytes, as well as c-MYC and Ki-67 expressions.

[Expert Opinion On Biological Therapy] The authors present completed and ongoing research projects regarding prostate cancer immunotherapy. Ipilimumab and olaparib were proved to prolong overall survival significantly against placebo, but a lot of research is going on to identify which patients and at what stage of disease will benefit the most before incorporating them in clinical practice.

[Advanced Materials] IFN-γ treatment induced remarkable PD-L1 expression on PD-L1-expressing macrophage membrane (PRM), thereby allowing PRM nanodecoys to bind mPD-1 on CD4+ T cell surfaces or neutralize free sPD-1, which reconstructed the PD-1/PD-L1 inhibitory axis to suppress CD4+ T cell activation and restore immune tolerance.

[Virchows Archiv] The authors cover the evolution and latest updates of the CAP/ASCO guidelines relevant to these two important biomarkers in breast cancer.

[Ascletis Pharma, Inc.] Ascletis Pharma, Inc. announced the Investigational New Drug (IND) application approval by US FDA and initiation of global development of ASC22, a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B.

[Journal of Pathology Clinical Research] The authors investigated the expression of two PD-1 ligands, PD-L1 and PD-L2, in pancreatic ductal adenocarcinoma, analysed their role in survival, and explored their correlation with clinicopathological features, immune infiltration, and DNA damage response molecules.